Skip to main content

Advertisement

Table 2 Analysis results for the top genes including new and already established driver gene candidates. The table is split according to top 10 oncogene candidates (A) and top 10 tumor suppressor gene candidates (B)

From: A genome-wide approach to link genotype to clinical outcome by utilizing next generation sequencing and gene chip data of 6,697 breast cancer patients

Gene % of samples w/ mutations Genes from ROC analysis (n) Upregulated genes Downregulated genes
P value HR P value HR
(A)
AKT1 5.5 136 <1E-16 1.8 1.60E-15 0.64
ATG2B 5.1 20 6.70E-09 1.4 6.90E-14 0.66
COL6A2 5.3 151 3.60E-13 1.5 1.50E-09 0.72
MTUS2 5.8 97 6.90E-06 1.3 1.10E-16 0.63
OSBPL10 5.2 46 2.40E-08 1.4 1.80E-12 0.68
POTEF 5.7 16 1.60E-11 1.4 5.60E-16 0.64
SCLT1 5.5 27 3.90E-08 1.4 5.10E-13 0.67
TNC 6 15 1.10E-07 1.3 <1E-16 0.63
TRANK1 5.3 10 <1E-16 1.7 1.90E-05 0.79
TRAPPC10 6.1 3 <1E-16 1.7 2.60E-11 0.69
(B)
ARFGEF1 6.4 63 <1E-16 0.52 <1E-16 1.7
BRCA2 6 74 <1E-16 0.52 2.20E-16 1.6
GGA3 5.5 359 <1E-16 0.49 1.40E-14 1.5
MPP6 5.5 48 <1E-16 0.53 <1E-16 1.8
PHEX 6.6 20 <1E-16 0.47 2.60E-15 1.5
PXDNL 6.1 255 <1E-16 0.51 <1E-16 1.6
RGS22 6 350 <1E-16 0.5 <1E-16 1.7
TP53 28.3 1566 <1E-16 0.48 5.60E-16 1.6
UBR5 9.9 8 <1E-16 0.53 <1E-16 1.7
UNC5D 6.6 51 <1E-16 0.54 <1E-16 1.8
  1. Significant signatures identified had to have an AUC value over 0.65 and a P value below 0.01 in the ROC analysis and an average HR over 1.4 and a P value below 0.01 in the survival analysis
  2. HR and P value: results of the Cox regression for both up- and downregulated genes